# A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

> **NCT06769412** · — · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 550000 (actual)

## Conditions studied

- Retinal Vasculitis

## Interventions

- **DRUG:** aflibercept 2 mg

## Key facts

- **NCT ID:** NCT06769412
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-01
- **Primary completion:** 2025-08-15
- **Final completion:** 2025-09-01
- **Target enrollment:** 550000 (ACTUAL)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06769412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06769412, "A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06769412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*